Prostate cancer classified as Gleason score 2 (G2) is generally considered low- to intermediate-risk and can be treated successfully with surgery in suitable patients. At this stage, the disease's biological behavior plays an important role in treatment planning.
The treatment approach for Gleason 2 prostate cancer is determined by taking the patient's age, general health, the tumor's local extent and expectations into account. Laparoscopic surgery may be considered a minimally invasive option in selected patients.
Diagnosing Gleason 2 prostate cancer involves evaluating PSA level, prostate biopsy results, clinical examination and imaging together. The tumor's status within the prostate capsule and its relationship to surrounding tissue are analyzed in detail to clarify the disease's stage.
This evaluation guides the suitability and scope of the surgical treatment.
Laparoscopic surgery for Gleason 2 prostate cancer is a minimally invasive surgical method aimed at removing the entire prostate gland. Performed through small incisions with a camera and specialized instruments, this approach allows for greater surgical precision.
Laparoscopic surgery can offer advantages such as less bleeding, a faster recovery and a shorter hospital stay. With proper patient selection, safe and effective results are the aim.
After surgery, patients are placed on a regular follow-up program. The course of the disease is monitored with PSA checks, clinical assessments and necessary imaging.
The goal of the treatment process is to control the cancer, preserve functional outcomes and maintain the patient's quality of life at the best possible level.
